Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × ceralasertib × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Breast Neoplasms 3 Neoplasms 2 Endometrial Neoplasms 2 Carcinosarcoma 2 Advanced Solid Tumours 2 Uterine Cervical Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Solid Tumour Refractory to Conventional Treatment 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Lung Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 High Grade Serous Carcinoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 121 Nivolumab 108 Ipilimumab 65 Cyclophosphamide 29 Specimen Handling 25 Magnetic Resonance Spectroscopy 23 trametinib 22 fludarabine 18 Interleukin-2 18 binimetinib 17 dabrafenib 16 atezolizumab 15 Radiosurgery 15 Biopsy 15 relatlimab 14 encorafenib 14 aldesleukin 14 Opdualag 14 cemiplimab 13 CTLA-4 Antigen 13 fludarabine phosphate 12 lenvatinib 10 Radiotherapy 10 Bevacizumab 10 spartalizumab 9 Cisplatin 9 cobimetinib 8 Vemurafenib 8 Blood Specimen Collection 8 Radiation 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡